2. GROUP MEMBERS
Priya Doshi
Richa Talati
Ronak Soni
Shibin Jacob
Sneha kapadia
Vikas verma

3. TABLE OF CONTENT
Introduction, Industry Profile, Company Profile, Vision, Mission –

4. INDUSTRY PROFILE
 The Indian Pharmaceutical Industry today is in the first
rank of India’s science based industries.
 The Indian Pharma Industry is estimated to be worth $
4.5 billion, growing at about 8 to 9 percent annually.
 The Indian Pharmaceutical sector is highly fragmented
with more than 20,000 registered units.

5. COMPANY PROFILE
 Ranbaxy Laboratories Limited, India's largest
pharmaceutical company.
 Ranked 8th amongst the global generic pharmaceutical
companies.
 The Company has a global footprint in 49 countries.
 World-class manufacturing facilities in 11 countries and
serves customers in over 125 countries.
 R&D has a pool of over 1,200 scientists engaged in
research.

6. Perhaps the largest front-end in the generic industry
BRICS Other Emerging
Markets
• No. 1 in India • 43/54 countries in Africa
• Large, reputed player in • Latam & Asia Pacific:
CIS; growing rapidly long standing presence;
• No. 6 in Brazil good understanding;
• No. 5 in S. Africa robust businesses
North America & Europe
Japan
• Pioneer entrant from • Well established
India • 23/25 EU markets
• Strong local presence • No. 1 Generic player in
• Canada: New market, Romania
growing rapidly
Ground presence in 49 countries; products sold in 125

7. MISSION
To become a research
based international
pharmaceutical company.

8. VISION
 Achieving customer satisfaction is fundamental to our business.
 Provide product and service of the highest quality.
 Manage our operation with high concern for strategy and
environment.
 Be a responsible corporate citizen

9. MILESTONES
 Ranbaxy entered in Golden Jubilee year.
 For the year 2008, the Company recorded Global Sales of US $
1,682 Mn
 Ranbaxy launches First to file (FTF) product , Donepezil
hydrochloride Tablets 5 mg and 10 mg with 180 days market
exclusively in the U.S. healthcare system.
 Ranbaxy delivered quarterly sales of over US $ 500Mn for the
first time.

10. Marketing

12. Strengths Weakness
• Low cost of production • Low on Capital Goods
• Efficient technology for • Low on key R&D
large no. of Generics • Less usage Bio-
• Skilled manpower technology for New Drug
Discovery Systems
Opportunities Threats
• Growing attention for health • High cost of discovering new
• New therapy approaches products
• Globalization • Stricter registration
• Growing income-levels procedures
• High entry cost in new
markets

13.  Among top 10 Global generic drugs company.
 Manufacturing operations in 11 countries, ground
presence in 49 countries and serves 125+ countries.
 Expanding international portfolio of affiliates and JVs
 International business generate 80% sales.
 Strong market presence and distribution network.
 State-of-the-art multi-disciplinary research facilities.

14.  Flexible
and efficient supply chain structure ensures
stable access to raw materials, systematic
manufacturing and timely, reliable delivery.
 Ranbaxy- Daiichi Sankyo Tie-up
Ranbaxy- access to Daiichi’s expertise in research
Daiichi - benefit from low-cost production

15. KEY COMPETENCIES

17. EMPLOYERS
SHAREHOLDERS RANBAXY INVESTORS
CUSTOMERS

18. HR

19. EMPLOYER EXPECTATION
 Good working condition
 Employee satisfaction toward salary.
 Proper assigned of works and goals.

20. RETENTION POLICY
 Training programs
 Management trainee programs.
 Through salaries and various other benefit.

21. TRAINING AND DEVELOPMENT
 There basic is to understand the business through
lecturer and interactive session.
 Project work in various areas of the key
function, across different location.
 Self –awareness session also provided.
 Self development with training on key behavior
attitudes.

22. PERFORMANCE APPRAISAL
 It is used as a to measure the performance of employee
s in the organization to check the progress towards the
desired goals and aims.
 Performance appraisal helps to rate the performance of
the employees and evaluate their contribution towards
the organizational goals.
 Performance appraisal takes into account the past
performance of the employees and focuses on the
improvement of the future performance of the
employees.

23. HEALTH AND SAFETY MEASURE
 They are totally committed to maintain high
standards of health and safety at the
workplace .
 They try to be sensitive to protection of the
environment by responsible management of
waste and pollution.

24. Finance

26. Revenue Breakdown
Global Revenue RoW
$1,667 $203, +6 Asia
$1,619 Europe
$1,400 % $465, +3
$1,339 $328, -
%
10%
North
America
CIS $443
2006 2007 2008 2009 (F)* $111, +24 , +6%
%
Favourable Market Mix
 Revenues spread across geographies
 Growing share of high growth, sustainable branded
business in Emerging Markets
 Substantial presence in regulated, western markets: high
volume base business + large Para-IV / FTF opportunities

27. COST DRIVERS
 Raw material
 R&D
 Patent of product ( Process patent & Drug patent)
 Packaging
 Logistics
 Ware housing ( self & contracted )

29. http://www.ranbaxy.com/investorinformati
on/irglance.aspx

30. Last
quarter
December
2010

31. RECENT NEWS

32. MYLAN SUES US FDA TO BLOCK LIPITOR LAUNCH
BY RANBAXY MARCH 21, 2011
Source: Business standard of 22nd March 2011

33. MERCK, RANBAXY DRUG DEVELOPMENT DEAL CALLED
OFF JANUARY 6, 2011

34. CONCLUSION

35. BIBLIOGRAPHY
 www.ranbaxy.com
 www.moneycontrol.com
 www.ndtvprofit.com